• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

For­ma­tion Bio’s up to €545M li­cens­ing deal with Sanofi; Ot­su­ka, Har­bour Bio­Med team up

3 weeks ago
News Briefing

Cidara near­ly dou­bles in val­ue as an­tivi­ral bi­o­log­ic pre­vents flu in mid-stage tri­al

3 weeks ago
R&D

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

3 weeks ago
People
FDA+

Lil­ly’s bima­grum­ab boosts weight and fat loss when added to Novo's We­govy

3 weeks ago
R&D

Il­lu­mi­na to buy So­ma­Log­ic for $350M up­front, push­ing fur­ther in­to pro­teomics

3 weeks ago
Deals
Diagnostics

Up­dat­ed: Com­pass claims Phase 3 win in de­pres­sion for psilo­cy­bin drug, yet stock plum­mets

3 weeks ago
R&D

Up­dat­ed: A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

3 weeks ago
R&D

FDA un­veils new pi­lot pro­gram; Sage finds a buy­er; Eli Lil­ly to ac­quire Verve; and more

3 weeks ago
Weekly

Ver­tex's di­a­betes cell ther­a­py al­lows 10 pa­tients to come off in­sulin

3 weeks ago
R&D
Cell/Gene Tx

CHMP rec­om­mends five new drugs, re­con­sid­ers Eli Lil­ly’s Kisun­la 

3 weeks ago
Pharma
FDA+

In­side the FDA’s ‘lis­ten­ing’ tour: Of­fi­cials agree US lags be­hind Chi­na on drug de­vel­op­ment

3 weeks ago
R&D
FDA+

Phar­ma com­pa­nies are weigh­ing how a drug’s IP lo­ca­tion could im­pact tar­iffs

3 weeks ago
Pharma
Manufacturing

UK's NICE says Lil­ly, Ei­sai's Alzheimer's drugs aren't worth na­tion­al cov­er­age

3 weeks ago
Pharma

Ear­ly-stage in­vestor Syn­cona read­justs pri­or­i­ties due to bleak biotech mar­ket

3 weeks ago
Financing
Startups

FDA OKs new la­bel ex­pan­sions for Dupix­ent and In­cyte's Mon­ju­vi

3 weeks ago
News Briefing

En­zene, Ve­r­a­no­va sep­a­rate­ly un­veil ex­pan­sions; Lot­te's new ADC client

3 weeks ago
Manufacturing

Roche's ven­ture arm chief to step down in 2026; As­traZeneca obe­si­ty leader has re­tired

3 weeks ago
Peer Review

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

3 weeks ago
Cell/Gene Tx
FDA+

Grail shares jump on study re­sults for can­cer test

3 weeks ago
Pharma
Diagnostics

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

3 weeks ago
Pharma
FDA+

Com­pounders lose case over semaglu­tide short­age

3 weeks ago
Pharma
Health Tech

Zealand study shows high­er GLP-1/GLP-2 dos­es may lead to greater weight loss

3 weeks ago
R&D

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

3 weeks ago
Pharma
FDA+

Q&A: New BIO chair to steer in­dus­try through ‘ex­is­ten­tial threats’ de­spite FDA re­cep­tiv­i­ty

3 weeks ago
R&D
China
First page Previous page 45678910 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times